Expert Pitch
University of Georgia

Professor: Information key to COVID-19 vaccine acceptance

8-Sep-2020 4:25 PM EDT, by University of Georgia

Glen Nowak, director of the Center for Health and Risk Communication at the University of Georgia, co-authored a Perspective article addressing one of the most pressing topics facing the United States: achieving high acceptance of a vaccine for COVID-19.

The article, “When Will We Have a Vaccine? — Understanding Questions and Answers about Covid-19 Vaccination,” was published Sept. 8 in the New England Journal of Medicine. It is co-authored by Barry R. Bloom of the Harvard T.H. Chan School of Public Health, and Walter Orenstein of the Emory Vaccine Center at Emory University School of Medicine. 

The Perspective calls attention to the activities and outcomes that need to be achieved before a COVID-19 vaccine is recommended and available for use in the United States. It notes that many people, including health care providers and journalists, are asking, “When will we have a vaccine to protect us against COVID-19?” Nowak and his co-authors point out those who ask that question really are asking three questions:  

  1. When will the public be able to have confidence that available COVID-19 vaccines are safe and effective?
  2. When will a COVID-19 vaccine be available to the general public?
  3. When will COVID-19 vaccination rates be high enough that society can return to a pre-pandemic world?

“Our perspective article provides advice on what is needed to achieve high confidence in COVID-19 vaccines,” said Nowak, a professor at the Grady College of Journalism and Mass Communication. “In the U.S., billions of dollars have been invested in developing COVID-19 vaccines, including five that are currently being tested with people. However, it is not enough to have a safe and effective COVID-19 vaccine. Most people need to be willing to be vaccinated. To achieve that, we need visible COVID-19 vaccine education efforts that involve transparency, engagement and dialogue.”

Nowak noted that investments and efforts in health care provider and public education about a new vaccine usually do not happen until there is a vaccination recommendation. Those efforts typically receive relatively little government funding and often only focus on health care providers.

“Oftentimes, it is assumed by many experts that new vaccines will speak for themselves. That is, their benefits are so obvious and important people will want to get vaccinated,” Nowak said.  “What usually happens, though, is health care providers and the people who should receive the new vaccine have many questions and concerns. They want to know how safety was determined and how well the vaccine will protect them.”  

The NEJM Perspective article is intended to provide guidance to federal and state government agencies and health officials who are hoping new COVID-19 vaccines will be widely accepted by the public. This includes the U.S. Department of Health and Human Services, the Federal Drug Administration, the National Institutes of Health and the Centers for Disease Control and Prevention.

Nowak said a broader, more in-depth approach needs to be taken starting now when it comes to communicating and educating people about the COVID-19 vaccines. Officials need to be transparent and communicate often about how vaccines are being evaluated for safety and effectiveness as well as how it was determined which groups of people should receive the first available doses.

There also need to be steps taken now that will help get as much acceptance as possible when the vaccine is ready, especially for those who are first in line to get it. This can be done through trusted health care professionals and user-friendly materials that provide safety and effectiveness information.

“As much as we all want the COVID-19 pandemic to end, we can’t assume fast and widespread acceptance of COVID-19 vaccines,” Nowak said. “We need to build trust and confidence in how these vaccines were developed and tested if we expect to achieve high acceptance.”

Nowak and Orenstein worked together at the CDC when Nowak was the director of communications for the National Immunization Program and Orenstein directed the program. Currently, Nowak serves on the National Vaccine Advisory Committee’s subcommittee on vaccine confidence. He is also working on research focusing on COVID-19 vaccine acceptance. 

 




Filters close

Showing results

110 of 3386
Released: 24-Sep-2020 11:45 AM EDT
How the Loss of Black-Owned Doctors’ Offices May Worsen Health Disparities
Rutgers University-New Brunswick

Rutgers New Jersey Medical School experts discuss how the loss of Black-Owned doctors’ offices could affect primary care access in minority communities and what impact the COVID-19 pandemic is having in those communities.

Released: 24-Sep-2020 11:15 AM EDT
Preparing for asthma attacks during a pandemic
University of Texas Health Science Center at Houston

Cooler weather, pumpkins, and falling leaves – all things that kick off the most wonderful time of year, the holiday season. But for asthma sufferers, this could mean trouble because experts see an increase in asthma attacks toward the end of September.

Newswise: Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
Released: 24-Sep-2020 11:10 AM EDT
Double-lung transplant for COVID-19 patient performed by team of UTHealth physicians
University of Texas Health Science Center at Houston

Just 12 hours after undergoing a double-lung transplant, 70-year-old Francisco Medellin was sitting up in a chair pushing bike pedals – a seemingly simple act that was the culmination of hard work by a dedicated multidisciplinary team from McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

Newswise: Antibodies protect against wide range of influenza B virus strains
22-Sep-2020 11:50 AM EDT
Antibodies protect against wide range of influenza B virus strains
Washington University in St. Louis

Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St. Louis and Icahn School of Medicine at Mount Sinai. Together with an antibody that targets the other major kind of influenza viruses that infect people — influenza A — these antibodies potentially could form the basis of a broad-spectrum flu drug that could treat almost all flu cases.

Released: 24-Sep-2020 10:45 AM EDT
Uncovering a ‘suPAR’ culprit behind kidney injury in COVID-19
Michigan Medicine - University of Michigan

A new observational study finds patients in the hospital for COVID-19 have high levels of soluble urokinase receptor (suPAR), an immune-derived pathogenic protein that is strongly predictive of kidney injury.

Released: 24-Sep-2020 10:35 AM EDT
Climate pledges 'like tackling COVID-19 without social distancing'
University of Exeter

Current global pledges to tackle climate change are the equivalent of declaring a pandemic without a plan for social distancing, researchers say.

Released: 24-Sep-2020 10:10 AM EDT
Rebound or Permanent Slump? Possible Impacts of US COVID-19 Fiscal Policies
University of Virginia Darden School of Business

Fiscal policy is a powerful tool to combat economic downturns, but the results depend on decreasing inequality, an imperative to the efficacy of fiscal multipliers. As COVID-19 cases rise, new research offers insights into which fiscal policies may bolster the economy — and the other options, which may have long-term ramifications.

access_time Embargo lifts in 2 days
Embargo will expire: 24-Sep-2020 2:00 PM EDT Released to reporters: 24-Sep-2020 9:25 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 24-Sep-2020 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 24-Sep-2020 5:05 AM EDT
Many Americans continue to maintain unhealthy lifestyle habits during COVID-19; overeating, alcohol drinking and marijuana use increase while exercise declines, reports USC Center for the Digital Future
USC Annenberg School for Communication and Journalism

After more than six months of living in a pandemic, large percentages of Americans continue to indulge in unhealthy lifestyle habits, including overeating and increased use of alcohol and marijuana — all while many are exercising less, according to a study of the cultural impact of COVID-19 conducted by the USC Center for the Digital Future (CDF).

Newswise: Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Released: 23-Sep-2020 4:55 PM EDT
Houston Methodist COVID-19 study shows rapid spread and potential for mutant viruses
Houston Methodist

Molecular analysis of COVID-19’s powerful second wave in Houston shows a mutated virus strain linked to higher transmission and infection rates than the coronavirus strains that caused Houston’s first wave. Gene sequencing results from 5,085 COVID-positive patients tested at Houston Methodist since early March show a virus capable of adapting, surviving and thriving – making it more important than ever for physician scientists to understand its evolution as they work to discover effective vaccines and therapies.


Showing results

110 of 3386

close
0.76611